MARINA KONOPLEVA to Sirolimus
This is a "connection" page, showing publications MARINA KONOPLEVA has written about Sirolimus.
Connection Strength
0.385
-
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood. 2007 Apr 15; 109(8):3509-12.
Score: 0.205
-
Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood. 2012 Sep 27; 120(13):2679-89.
Score: 0.075
-
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006 Sep 01; 12(17):5165-73.
Score: 0.050
-
Activated B cells suppress T-cell function through metabolic competition. J Immunother Cancer. 2022 12; 10(12).
Score: 0.039
-
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med. 2010 Feb; 16(2):205-13.
Score: 0.016